Funding for this research was provided by:
Charité – Universitätsmedizin Berlin
Received: 10 January 2019
Accepted: 22 April 2019
First Online: 23 May 2019
Ethics approval and consent to participate
: The study has been approved by the local ethics committee of the Charité - Universitätsmedizin Berlin (EA1/005/15). All patients participating in the study provided written informed consent to participate in the study.
: Jan Hoffmann has consulted for and/or serves on advisory boards for Allergan, Autonomic Technologies Inc. (ATI), Chordate Medical AB, Eli Lilly, Hormosan Pharma, Novartis and Teva. He received honoraria for speaking from Allergan, Autonomic Technologies Inc. (ATI), Chordate Medical AB, Novartis and Teva. These activities are unrelated to the content of this manuscript.Katharina Maria Kreutz reports no conflict of interest.Christoph Csapó-Schmidt reports no conflict of interest.Nils Becker reports no conflict of interest.Hagen Kunte received personal compensation for speaking from Biogen-Idec, Norvartis, Genzyme, Teva, Merck, Mylan, and Bayer. He also received honoraria for participation in advisory boards from Norvartis, Roche, Genzyme, and Teva as well as travel support to congresses by Norvartis, Genzyme, Teva.Lucius Samo Fekonja reports no conflict of interest.Anas Jadan reports no conflict of interest.Edzard Wiener reports no conflict of interest.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.